Filgrastim products ruled bioequivalent

The PBAC has recommended that filgrastim (Neupogen) and its three biosimilars (Nivestim, Tevagrastim and Zarzio) can be marked as equivalent for the purposes of substitution. The decision, made at the PBAC’s April meeting and reported last week, applies to all indications including treatment of chemotherapy-induced and other neutropenias or for mobilisation of peripheral blood progenitor ...

Already a member?

Login to keep reading.

© 2021 the limbic